Caredx pushes back against CMS' steep proposed 74% Allomap test price cut
Molecular diagnostics company Caredx Inc. said it will not be able to provide Allomap tests to Medicare patients if a 74 percent reimbursement cut stands. The blood test is used to determine rejection risk in heart transplant recipients and, according to the company, it is the only alternative to the more invasive and riskier biopsy procedure.
Will innovation pay the price for med-tech biggering?
The urge to go on biggering and biggering and biggering has taken over the med-tech world. Barely a year after Zimmer and Biomet completed a $14 billion merger to become the second largest orthopedic device maker, the company now plans to spend another $1 billion to buy LDR and grow its spine business. (MDD Perspectives)
Closing of $175M Asia VC fund underlines core opportunities in the medical device space
HONG KONG In the midst of technological advancements that are disrupting the traditional health technology industry, some venture capital (VC) funds are reaping significant benefits by jumping into the medical device space in Asia in the formative days of the companies.